Form 4 for SONM DNA X, Inc.
Accepted 2026-02-10 00:00:00 ET · period of report 2026-02-09 · accession 0001493152-26-006053 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-10 | 2026-02-09 | SONM | MULICA MICHAEL C | Acting CEO, Dir | A - Grant | $0.00 | +50.0K | 54.1K | +1,228% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-09 | A | A | 50,000 | $0.00 | 54,071 | D | — | — | (F1) Represents the grant of restricted stock units that vest in equal monthly installments over a one-year period following the date of the grant, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. (F2) Consists of (i) 4,071 shares of common stock and (ii) 50,000 unvested restricted stock units. (F3) The number of securities reported herein reflects the effects of a 1-for-18 reverse stock split effected by the Issuer on October 27, 2025, which was exempt from reporting pursuant to Rule 16a-9. |